COMBIHALE FB 400 RESPICAPS

Description

COMBIHALE FB 400 RESPICAPS contain a fixed-dose combination of Formoterol Fumarate (400 mcg), a long-acting beta-2 agonist (LABA), and Budesonide (400 mcg), an inhaled corticosteroid (ICS). This combination therapy provides both bronchodilation and anti-inflammatory effects, essential for the long-term management of asthma and chronic obstructive pulmonary disease (COPD).

Formoterol helps relax the airway muscles to improve airflow, while budesonide reduces inflammation in the airways, preventing asthma attacks and COPD exacerbations. The RESPICAPS are designed for use with a dry powder inhaler device to deliver medication directly to the lungs for maximum efficacy.

Key Benefits:

• Dual-action inhalation therapy for enhanced symptom control

• Reduces airway inflammation and bronchoconstriction

• Prevents exacerbations and improves lung function

• Convenient capsule form for inhalation via dry powder inhaler

Indications:

• Maintenance treatment of asthma

• Management of chronic obstructive pulmonary disease (COPD)

Dosage:
As prescribed by the physician, usually inhaling the contents of one capsule twice daily using the inhaler device.

Precautions:
Not for acute asthma attacks. Use only under medical supervision. Possible side effects include tremors, headache, and oral thrush.